By Denny Jacob

Biora Therapeutics' investigational new drug application for moderate to severe ulcerative colitis treatment BT-600 was cleared by the Food and Drug Administration.

Ariella Kelman, chief medical officer of the biotech company, said Biora will complete activities required by the FDA and trial site prior to enrolling the first subject in its Phase 1 clinical trial in the U.S. in the coming weeks.

Write to Denny Jacob at denny.jacob@wsj.com

(END) Dow Jones Newswires

November 30, 2023 17:14 ET (22:14 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Biora Therapeutics (NASDAQ:BIOR)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024 Biora Therapeutics 차트를 더 보려면 여기를 클릭.
Biora Therapeutics (NASDAQ:BIOR)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024 Biora Therapeutics 차트를 더 보려면 여기를 클릭.